| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 39 | 2024 | 767 | 10.770 |
Why?
|
| Cardiovascular Diseases | 48 | 2024 | 1122 | 9.930 |
Why?
|
| Coronary Artery Disease | 32 | 2024 | 398 | 7.430 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 19 | 2023 | 144 | 6.480 |
Why?
|
| Hyperlipoproteinemia Type II | 14 | 2023 | 17 | 5.890 |
Why?
|
| Anticholesteremic Agents | 12 | 2023 | 39 | 5.880 |
Why?
|
| Dyslipidemias | 11 | 2024 | 53 | 4.780 |
Why?
|
| Hypercholesterolemia | 11 | 2023 | 69 | 4.780 |
Why?
|
| Lipoprotein(a) | 13 | 2023 | 21 | 4.720 |
Why?
|
| Cardiology | 12 | 2024 | 99 | 4.610 |
Why?
|
| Cholesterol, LDL | 20 | 2024 | 173 | 4.510 |
Why?
|
| Humans | 160 | 2024 | 31836 | 3.130 |
Why?
|
| Tomography, X-Ray Computed | 26 | 2020 | 912 | 3.070 |
Why?
|
| Risk Factors | 49 | 2024 | 3851 | 2.650 |
Why?
|
| Lipids | 9 | 2024 | 228 | 2.600 |
Why?
|
| Coronary Angiography | 18 | 2024 | 148 | 2.550 |
Why?
|
| Preventive Medicine | 5 | 2021 | 9 | 2.380 |
Why?
|
| Antibodies, Monoclonal | 7 | 2019 | 244 | 2.380 |
Why?
|
| Cholesterol | 10 | 2024 | 251 | 2.000 |
Why?
|
| Risk Assessment | 23 | 2024 | 1431 | 2.000 |
Why?
|
| Coronary Vessels | 10 | 2024 | 158 | 1.910 |
Why?
|
| Hypertriglyceridemia | 4 | 2022 | 8 | 1.710 |
Why?
|
| Coronary Disease | 8 | 2024 | 213 | 1.700 |
Why?
|
| Cardiovascular System | 3 | 2024 | 43 | 1.690 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 2020 | 6 | 1.510 |
Why?
|
| Myocardial Infarction | 13 | 2023 | 480 | 1.510 |
Why?
|
| Calcium | 9 | 2024 | 304 | 1.500 |
Why?
|
| Middle Aged | 65 | 2024 | 11824 | 1.490 |
Why?
|
| Lipoproteins | 4 | 2022 | 84 | 1.360 |
Why?
|
| Male | 76 | 2024 | 19091 | 1.260 |
Why?
|
| Chest Pain | 10 | 2023 | 207 | 1.240 |
Why?
|
| Acute Coronary Syndrome | 9 | 2016 | 193 | 1.230 |
Why?
|
| Treatment Outcome | 18 | 2023 | 3294 | 1.220 |
Why?
|
| Female | 71 | 2024 | 19859 | 1.190 |
Why?
|
| Primary Prevention | 6 | 2023 | 54 | 1.190 |
Why?
|
| United States | 25 | 2024 | 3925 | 1.110 |
Why?
|
| Diabetes Mellitus | 7 | 2024 | 409 | 1.050 |
Why?
|
| Hyperlipidemias | 3 | 2023 | 54 | 1.020 |
Why?
|
| C-Reactive Protein | 4 | 2024 | 239 | 1.000 |
Why?
|
| Aged | 36 | 2024 | 10288 | 0.990 |
Why?
|
| Triglycerides | 5 | 2024 | 230 | 0.950 |
Why?
|
| Ketocholesterols | 1 | 2023 | 1 | 0.920 |
Why?
|
| Predictive Value of Tests | 15 | 2023 | 874 | 0.900 |
Why?
|
| Prediabetic State | 2 | 2023 | 65 | 0.890 |
Why?
|
| American Heart Association | 2 | 2020 | 87 | 0.870 |
Why?
|
| Adult | 36 | 2024 | 9327 | 0.850 |
Why?
|
| Risk Reduction Behavior | 3 | 2019 | 125 | 0.800 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 404 | 0.800 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 36 | 0.790 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 21 | 0.780 |
Why?
|
| Evidence-Based Medicine | 2 | 2019 | 215 | 0.720 |
Why?
|
| Family Practice | 2 | 2023 | 51 | 0.720 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 114 | 0.680 |
Why?
|
| Apolipoproteins | 1 | 2021 | 200 | 0.680 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 22 | 0.670 |
Why?
|
| Niacin | 1 | 2019 | 7 | 0.670 |
Why?
|
| Hypertension | 4 | 2023 | 956 | 0.670 |
Why?
|
| Aspirin | 1 | 2019 | 64 | 0.660 |
Why?
|
| Mutation | 4 | 2018 | 487 | 0.660 |
Why?
|
| Cannabis | 1 | 2019 | 23 | 0.650 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2016 | 227 | 0.650 |
Why?
|
| Drug Costs | 1 | 2019 | 47 | 0.640 |
Why?
|
| Prospective Studies | 19 | 2023 | 2277 | 0.620 |
Why?
|
| Pancreatitis | 1 | 2018 | 22 | 0.620 |
Why?
|
| Drug Resistance | 1 | 2017 | 39 | 0.600 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 271 | 0.590 |
Why?
|
| Wolman Disease | 1 | 2017 | 2 | 0.580 |
Why?
|
| Inflammation | 3 | 2023 | 540 | 0.580 |
Why?
|
| Drugs, Investigational | 1 | 2016 | 6 | 0.540 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 147 | 0.540 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 2 | 0.510 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 105 | 0.510 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 97 | 0.500 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2010 | 1323 | 0.500 |
Why?
|
| Aortic Valve Stenosis | 2 | 2023 | 29 | 0.490 |
Why?
|
| Prognosis | 9 | 2024 | 1498 | 0.480 |
Why?
|
| Decision Support Systems, Clinical | 5 | 2012 | 57 | 0.460 |
Why?
|
| Columbidae | 1 | 2013 | 1 | 0.460 |
Why?
|
| Pigmentation | 1 | 2013 | 6 | 0.460 |
Why?
|
| Melanins | 1 | 2013 | 6 | 0.460 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2013 | 6 | 0.460 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 39 | 0.450 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 240 | 0.450 |
Why?
|
| Blood Glucose | 3 | 2021 | 491 | 0.450 |
Why?
|
| Time Factors | 7 | 2019 | 2146 | 0.450 |
Why?
|
| Cross-Sectional Studies | 12 | 2023 | 1527 | 0.450 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2010 | 27 | 0.450 |
Why?
|
| Exercise Test | 2 | 2016 | 225 | 0.440 |
Why?
|
| Cell Membrane | 1 | 2013 | 96 | 0.440 |
Why?
|
| Myocardial Revascularization | 3 | 2022 | 40 | 0.440 |
Why?
|
| Decision Making | 2 | 2022 | 194 | 0.430 |
Why?
|
| Myocardium | 4 | 2010 | 186 | 0.430 |
Why?
|
| Myocardial Ischemia | 3 | 2023 | 106 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 504 | 0.420 |
Why?
|
| Contrast Media | 10 | 2010 | 138 | 0.420 |
Why?
|
| Image Enhancement | 2 | 2009 | 72 | 0.410 |
Why?
|
| Aortography | 2 | 2009 | 16 | 0.400 |
Why?
|
| Sensitivity and Specificity | 11 | 2010 | 589 | 0.400 |
Why?
|
| Cohort Studies | 7 | 2021 | 1824 | 0.390 |
Why?
|
| Reperfusion Injury | 1 | 2011 | 49 | 0.370 |
Why?
|
| Pulmonary Veins | 2 | 2008 | 10 | 0.370 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 323 | 0.350 |
Why?
|
| Perfusion Imaging | 1 | 2009 | 8 | 0.350 |
Why?
|
| Animals | 9 | 2020 | 7450 | 0.340 |
Why?
|
| Kidney | 2 | 2023 | 515 | 0.330 |
Why?
|
| Heart Failure | 3 | 2024 | 620 | 0.330 |
Why?
|
| MicroRNAs | 1 | 2011 | 180 | 0.330 |
Why?
|
| Aged, 80 and over | 12 | 2023 | 3988 | 0.330 |
Why?
|
| Cause of Death | 3 | 2019 | 238 | 0.330 |
Why?
|
| Triiodobenzoic Acids | 7 | 2010 | 8 | 0.330 |
Why?
|
| Electrocardiography | 6 | 2016 | 632 | 0.320 |
Why?
|
| Early Diagnosis | 3 | 2024 | 62 | 0.310 |
Why?
|
| Aortic Diseases | 1 | 2009 | 63 | 0.310 |
Why?
|
| Pulmonary Embolism | 1 | 2009 | 49 | 0.310 |
Why?
|
| Stroke | 3 | 2023 | 581 | 0.310 |
Why?
|
| Healthcare Disparities | 4 | 2020 | 165 | 0.310 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2008 | 113 | 0.300 |
Why?
|
| Atrial Appendage | 1 | 2007 | 9 | 0.300 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2007 | 43 | 0.300 |
Why?
|
| Metoprolol | 1 | 2007 | 3 | 0.300 |
Why?
|
| Registries | 6 | 2020 | 295 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 835 | 0.290 |
Why?
|
| Angioplasty, Balloon | 1 | 2007 | 35 | 0.290 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2007 | 61 | 0.290 |
Why?
|
| Thrombosis | 1 | 2007 | 72 | 0.290 |
Why?
|
| Retrospective Studies | 9 | 2023 | 3488 | 0.290 |
Why?
|
| Phenotype | 5 | 2023 | 635 | 0.280 |
Why?
|
| Acute Disease | 5 | 2018 | 252 | 0.280 |
Why?
|
| Heart Diseases | 1 | 2007 | 115 | 0.270 |
Why?
|
| Emergency Service, Hospital | 6 | 2023 | 471 | 0.270 |
Why?
|
| Heart Rate | 2 | 2007 | 332 | 0.270 |
Why?
|
| Coronary Circulation | 4 | 2010 | 44 | 0.270 |
Why?
|
| Qualitative Research | 4 | 2020 | 166 | 0.240 |
Why?
|
| Ischemia | 2 | 2023 | 98 | 0.240 |
Why?
|
| Mortality | 2 | 2024 | 124 | 0.240 |
Why?
|
| Oregon | 3 | 2019 | 7 | 0.230 |
Why?
|
| Hospitalization | 4 | 2024 | 463 | 0.230 |
Why?
|
| Dicarboxylic Acids | 1 | 2023 | 7 | 0.230 |
Why?
|
| Sleep | 1 | 2024 | 92 | 0.220 |
Why?
|
| Radiographic Image Enhancement | 3 | 2007 | 26 | 0.220 |
Why?
|
| Heterozygote | 3 | 2019 | 57 | 0.210 |
Why?
|
| Liver Diseases | 1 | 2023 | 70 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1424 | 0.210 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 2271 | 0.210 |
Why?
|
| Fatty Acids | 1 | 2023 | 97 | 0.210 |
Why?
|
| Substance-Related Disorders | 1 | 2024 | 127 | 0.210 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 298 | 0.210 |
Why?
|
| Drug Interactions | 1 | 2022 | 79 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2022 | 56 | 0.200 |
Why?
|
| History, 20th Century | 3 | 2019 | 71 | 0.200 |
Why?
|
| Biology | 1 | 2021 | 1 | 0.200 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2010 | 38 | 0.200 |
Why?
|
| Obesity | 4 | 2023 | 1158 | 0.200 |
Why?
|
| Natural History | 1 | 2021 | 2 | 0.200 |
Why?
|
| Telemedicine | 2 | 2020 | 99 | 0.200 |
Why?
|
| Lipid Metabolism | 2 | 2024 | 104 | 0.190 |
Why?
|
| Europe | 1 | 2021 | 83 | 0.190 |
Why?
|
| Education | 1 | 2021 | 39 | 0.190 |
Why?
|
| Diffusion of Innovation | 2 | 2019 | 34 | 0.190 |
Why?
|
| Spirituality | 1 | 2021 | 34 | 0.190 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 756 | 0.190 |
Why?
|
| Antihypertensive Agents | 2 | 2022 | 351 | 0.190 |
Why?
|
| Preventive Health Services | 1 | 2021 | 44 | 0.190 |
Why?
|
| Health Status Disparities | 2 | 2023 | 122 | 0.190 |
Why?
|
| Mice | 3 | 2018 | 2476 | 0.190 |
Why?
|
| Needs Assessment | 1 | 2021 | 76 | 0.190 |
Why?
|
| History, 21st Century | 2 | 2019 | 59 | 0.190 |
Why?
|
| Genome, Human | 2 | 2015 | 132 | 0.190 |
Why?
|
| Dairying | 1 | 2020 | 1 | 0.180 |
Why?
|
| Apolipoproteins B | 2 | 2017 | 46 | 0.180 |
Why?
|
| Diagnosis, Differential | 5 | 2010 | 518 | 0.180 |
Why?
|
| Ethnic Groups | 2 | 2020 | 476 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 28 | 0.180 |
Why?
|
| Dementia | 1 | 2023 | 251 | 0.180 |
Why?
|
| Young Adult | 6 | 2024 | 2603 | 0.180 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 288 | 0.180 |
Why?
|
| Logistic Models | 4 | 2020 | 777 | 0.180 |
Why?
|
| Secondary Prevention | 1 | 2020 | 62 | 0.170 |
Why?
|
| Oligonucleotides | 1 | 2020 | 30 | 0.170 |
Why?
|
| Medication Adherence | 2 | 2019 | 161 | 0.170 |
Why?
|
| Certification | 1 | 2019 | 27 | 0.170 |
Why?
|
| Professional Role | 1 | 2019 | 19 | 0.170 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 47 | 0.170 |
Why?
|
| Pharmacists | 1 | 2019 | 20 | 0.170 |
Why?
|
| Medical Assistance | 1 | 2019 | 3 | 0.170 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2010 | 169 | 0.170 |
Why?
|
| Education, Medical | 1 | 2019 | 68 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2019 | 17 | 0.160 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 549 | 0.160 |
Why?
|
| Life Style | 2 | 2020 | 407 | 0.160 |
Why?
|
| Calcinosis | 3 | 2009 | 145 | 0.160 |
Why?
|
| Internet | 1 | 2020 | 195 | 0.160 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 272 | 0.160 |
Why?
|
| Risk | 1 | 2019 | 318 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2019 | 100 | 0.160 |
Why?
|
| Adolescent | 6 | 2023 | 3511 | 0.160 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 39 | 0.160 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 284 | 0.160 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2010 | 103 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2019 | 66 | 0.160 |
Why?
|
| Angiography | 1 | 2018 | 80 | 0.150 |
Why?
|
| RNA Interference | 1 | 2018 | 76 | 0.150 |
Why?
|
| Hypobetalipoproteinemias | 1 | 2017 | 1 | 0.150 |
Why?
|
| Receptors, LDL | 1 | 2018 | 65 | 0.150 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 78 | 0.150 |
Why?
|
| Angiopoietins | 1 | 2017 | 2 | 0.150 |
Why?
|
| Survival Rate | 2 | 2017 | 884 | 0.150 |
Why?
|
| Odds Ratio | 4 | 2017 | 470 | 0.150 |
Why?
|
| Curriculum | 1 | 2019 | 208 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 300 | 0.150 |
Why?
|
| Tomography, Spiral Computed | 2 | 2008 | 18 | 0.150 |
Why?
|
| Ultrasonography, Doppler | 1 | 2017 | 23 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 155 | 0.150 |
Why?
|
| Cholesterol, HDL | 3 | 2024 | 177 | 0.150 |
Why?
|
| Income | 1 | 2017 | 61 | 0.150 |
Why?
|
| Social Class | 1 | 2017 | 88 | 0.150 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 29 | 0.150 |
Why?
|
| Ankle Brachial Index | 1 | 2017 | 38 | 0.150 |
Why?
|
| Smoking Cessation | 1 | 2019 | 197 | 0.140 |
Why?
|
| Artifacts | 2 | 2007 | 39 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 1067 | 0.140 |
Why?
|
| Mass Screening | 1 | 2019 | 263 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2019 | 225 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 184 | 0.140 |
Why?
|
| Base Sequence | 2 | 2015 | 251 | 0.140 |
Why?
|
| Vaccination | 1 | 2018 | 136 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 164 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 353 | 0.140 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 355 | 0.140 |
Why?
|
| Skin Diseases, Genetic | 1 | 2016 | 4 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 242 | 0.140 |
Why?
|
| Vascular Malformations | 1 | 2016 | 9 | 0.140 |
Why?
|
| Retinopathy of Prematurity | 1 | 2016 | 8 | 0.140 |
Why?
|
| Retinal Vessels | 1 | 2016 | 19 | 0.140 |
Why?
|
| Emergency Medical Services | 2 | 2009 | 178 | 0.130 |
Why?
|
| Genomic Structural Variation | 1 | 2015 | 1 | 0.130 |
Why?
|
| Arteries | 1 | 2016 | 67 | 0.130 |
Why?
|
| Coronary Stenosis | 4 | 2010 | 30 | 0.130 |
Why?
|
| Quality of Life | 1 | 2021 | 924 | 0.130 |
Why?
|
| Skull Fractures | 1 | 2015 | 17 | 0.130 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 899 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 145 | 0.130 |
Why?
|
| Electronic Health Records | 3 | 2011 | 159 | 0.130 |
Why?
|
| Aortic Valve | 2 | 2023 | 47 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 297 | 0.130 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 20 | 0.130 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 193 | 0.130 |
Why?
|
| Cervical Vertebrae | 1 | 2015 | 44 | 0.130 |
Why?
|
| Joint Instability | 1 | 2016 | 76 | 0.130 |
Why?
|
| Liver | 1 | 2018 | 482 | 0.120 |
Why?
|
| Spinal Fractures | 1 | 2015 | 43 | 0.120 |
Why?
|
| Heart | 3 | 2024 | 178 | 0.120 |
Why?
|
| Prevalence | 3 | 2024 | 979 | 0.120 |
Why?
|
| Comorbidity | 3 | 2023 | 566 | 0.120 |
Why?
|
| Genetic Variation | 1 | 2015 | 245 | 0.120 |
Why?
|
| Gadolinium DTPA | 3 | 2010 | 16 | 0.120 |
Why?
|
| Triage | 3 | 2010 | 72 | 0.120 |
Why?
|
| Feathers | 1 | 2013 | 1 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2013 | 20 | 0.110 |
Why?
|
| Principal Component Analysis | 2 | 2011 | 68 | 0.110 |
Why?
|
| Sequence Alignment | 1 | 2013 | 60 | 0.110 |
Why?
|
| Protestantism | 2 | 2023 | 7 | 0.110 |
Why?
|
| Haplotypes | 1 | 2013 | 220 | 0.110 |
Why?
|
| Florida | 2 | 2023 | 37 | 0.110 |
Why?
|
| Atrial Fibrillation | 2 | 2008 | 322 | 0.110 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 283 | 0.110 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 45 | 0.110 |
Why?
|
| Alleles | 1 | 2013 | 248 | 0.110 |
Why?
|
| Apolipoprotein C-III | 2 | 2022 | 5 | 0.100 |
Why?
|
| Algorithms | 1 | 2015 | 495 | 0.100 |
Why?
|
| Echocardiography | 3 | 2008 | 155 | 0.100 |
Why?
|
| Sex Factors | 3 | 2020 | 662 | 0.100 |
Why?
|
| Warm Ischemia | 1 | 2011 | 9 | 0.100 |
Why?
|
| Intra-Abdominal Fat | 1 | 2012 | 63 | 0.100 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 137 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2017 | 103 | 0.100 |
Why?
|
| Age Factors | 3 | 2024 | 1187 | 0.100 |
Why?
|
| Public Health | 2 | 2024 | 81 | 0.100 |
Why?
|
| Commerce | 1 | 2011 | 43 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2011 | 57 | 0.100 |
Why?
|
| Radiation Protection | 1 | 2011 | 7 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 37 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2023 | 190 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 686 | 0.090 |
Why?
|
| Myocardial Reperfusion | 2 | 2008 | 10 | 0.090 |
Why?
|
| Community Health Services | 1 | 2011 | 56 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2011 | 184 | 0.090 |
Why?
|
| Radiometry | 1 | 2011 | 39 | 0.090 |
Why?
|
| Disease Progression | 2 | 2024 | 593 | 0.090 |
Why?
|
| Single-Blind Method | 2 | 2009 | 201 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 83 | 0.090 |
Why?
|
| Tissue Survival | 1 | 2010 | 12 | 0.090 |
Why?
|
| Tunica Media | 1 | 2010 | 28 | 0.090 |
Why?
|
| Tunica Intima | 1 | 2010 | 57 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2010 | 26 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 39 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2008 | 22 | 0.090 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2009 | 11 | 0.090 |
Why?
|
| Incidence | 3 | 2024 | 1192 | 0.090 |
Why?
|
| Heart Ventricles | 2 | 2008 | 134 | 0.080 |
Why?
|
| Smegmamorpha | 1 | 2009 | 1 | 0.080 |
Why?
|
| Sex Chromosomes | 1 | 2009 | 4 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2010 | 199 | 0.080 |
Why?
|
| Angina Pectoris | 1 | 2009 | 22 | 0.080 |
Why?
|
| Collateral Circulation | 1 | 2008 | 9 | 0.080 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 24 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 766 | 0.080 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2008 | 12 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2009 | 99 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 493 | 0.080 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 85 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2008 | 66 | 0.080 |
Why?
|
| Length of Stay | 2 | 2023 | 315 | 0.080 |
Why?
|
| Angina, Unstable | 1 | 2008 | 21 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 45 | 0.080 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2007 | 1 | 0.080 |
Why?
|
| Stroke Volume | 3 | 2024 | 341 | 0.080 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2007 | 25 | 0.070 |
Why?
|
| Aorta | 1 | 2007 | 125 | 0.070 |
Why?
|
| California | 2 | 2021 | 61 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2006 | 53 | 0.070 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2006 | 37 | 0.070 |
Why?
|
| Tomography, Optical Coherence | 1 | 2006 | 45 | 0.070 |
Why?
|
| Age Distribution | 2 | 2021 | 206 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2006 | 115 | 0.060 |
Why?
|
| Pre-Excitation Syndromes | 1 | 2005 | 2 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2016 | 349 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 161 | 0.060 |
Why?
|
| Exercise | 2 | 2021 | 663 | 0.060 |
Why?
|
| Iran | 1 | 2023 | 4 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2024 | 58 | 0.060 |
Why?
|
| Gene Expression | 1 | 2005 | 334 | 0.060 |
Why?
|
| Southeastern United States | 1 | 2023 | 79 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 764 | 0.060 |
Why?
|
| Asia | 1 | 2023 | 19 | 0.060 |
Why?
|
| Self Efficacy | 1 | 2023 | 78 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2024 | 114 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 195 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 85 | 0.050 |
Why?
|
| ROC Curve | 2 | 2016 | 167 | 0.050 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2022 | 29 | 0.050 |
Why?
|
| Docosahexaenoic Acids | 1 | 2022 | 21 | 0.050 |
Why?
|
| Particle Size | 1 | 2022 | 46 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 305 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 12 | 0.050 |
Why?
|
| Calcium, Dietary | 1 | 2021 | 23 | 0.050 |
Why?
|
| New Mexico | 1 | 2021 | 6 | 0.050 |
Why?
|
| Arizona | 1 | 2021 | 8 | 0.050 |
Why?
|
| African Americans | 2 | 2020 | 1428 | 0.050 |
Why?
|
| Texas | 1 | 2021 | 36 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2017 | 916 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2022 | 108 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2022 | 186 | 0.050 |
Why?
|
| Mexico | 1 | 2021 | 71 | 0.050 |
Why?
|
| Inpatients | 1 | 2022 | 81 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2021 | 195 | 0.050 |
Why?
|
| Medicare | 1 | 2022 | 206 | 0.050 |
Why?
|
| Geography | 1 | 2020 | 34 | 0.050 |
Why?
|
| Animal Welfare | 1 | 2020 | 1 | 0.050 |
Why?
|
| Cattle Diseases | 1 | 2020 | 3 | 0.050 |
Why?
|
| New York | 1 | 2020 | 21 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2020 | 49 | 0.050 |
Why?
|
| Animal Husbandry | 1 | 2020 | 7 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2023 | 345 | 0.050 |
Why?
|
| Cattle | 1 | 2020 | 103 | 0.040 |
Why?
|
| Employment | 1 | 2020 | 48 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 276 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 33 | 0.040 |
Why?
|
| Rural Population | 1 | 2021 | 273 | 0.040 |
Why?
|
| Educational Status | 1 | 2020 | 178 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 70 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 98 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 262 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 34 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2023 | 843 | 0.040 |
Why?
|
| North Carolina | 1 | 2023 | 1514 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2020 | 185 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 99 | 0.040 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 103 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 159 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 523 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 132 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 629 | 0.040 |
Why?
|
| North America | 1 | 2017 | 32 | 0.040 |
Why?
|
| Pedigree | 1 | 2017 | 140 | 0.040 |
Why?
|
| Asian Americans | 1 | 2017 | 97 | 0.040 |
Why?
|
| Lipoproteins, LDL | 1 | 2017 | 81 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 771 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 135 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2017 | 292 | 0.040 |
Why?
|
| Singapore | 1 | 2016 | 10 | 0.030 |
Why?
|
| Expert Systems | 1 | 2016 | 4 | 0.030 |
Why?
|
| Patient Selection | 2 | 2011 | 276 | 0.030 |
Why?
|
| Radiopharmaceuticals | 2 | 2008 | 90 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2010 | 895 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 449 | 0.030 |
Why?
|
| Apolipoproteins A | 1 | 2016 | 25 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2016 | 32 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2016 | 68 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 201 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 1169 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 15 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 142 | 0.030 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2016 | 58 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2016 | 119 | 0.030 |
Why?
|
| Shock, Hemorrhagic | 1 | 2015 | 30 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2015 | 111 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 251 | 0.030 |
Why?
|
| Software | 1 | 2015 | 127 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 82 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2015 | 75 | 0.030 |
Why?
|
| Physicians | 1 | 2016 | 157 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2020 | 942 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 665 | 0.030 |
Why?
|
| Child | 1 | 2020 | 2425 | 0.030 |
Why?
|
| Institutional Management Teams | 1 | 2012 | 2 | 0.030 |
Why?
|
| Systems Analysis | 1 | 2012 | 3 | 0.030 |
Why?
|
| Health Planning Guidelines | 1 | 2012 | 5 | 0.030 |
Why?
|
| Inservice Training | 1 | 2012 | 12 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2012 | 11 | 0.030 |
Why?
|
| Research Personnel | 1 | 2012 | 15 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2012 | 90 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 48 | 0.020 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2011 | 6 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 11 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2011 | 31 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2011 | 81 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 180 | 0.020 |
Why?
|
| Homocysteine | 1 | 2010 | 14 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 91 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2010 | 76 | 0.020 |
Why?
|
| Rest | 1 | 2010 | 54 | 0.020 |
Why?
|
| Body Composition | 1 | 2012 | 388 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 293 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2009 | 20 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 34 | 0.020 |
Why?
|
| Phylogeny | 1 | 2009 | 54 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 148 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2008 | 1 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 158 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2010 | 378 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 73 | 0.020 |
Why?
|
| Observer Variation | 1 | 2006 | 105 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 487 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2006 | 64 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 73 | 0.020 |
Why?
|
| Cadaver | 1 | 2006 | 161 | 0.020 |
Why?
|
| Rubidium Radioisotopes | 1 | 2005 | 7 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 50 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2005 | 33 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2005 | 128 | 0.020 |
Why?
|
| Leukocytes | 1 | 2005 | 59 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 163 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 727 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 249 | 0.010 |
Why?
|